GLP1R and diabetes mellitus: The SURMOUNT-1 trial found that in people with overweight/obese but without diabetes, 72 weeks of the combined GLP-1/glucose-dependent insulinotropic peptide (GIP) agonist, tirzepatide, at doses of 5, 10, or 15 mg led to 15.0, 19.5, and 20.9% weight loss, respectively, compared with 3.1% in people taking placebo [9].